Tin tức & Cập nhật

Maintenance treatment with niraparib, a potent, highly selective PARP* inhibitor, provides a favourable overall survival (OS) trend compared with placebo in Chinese patients with platinum-sensitive recurrent ovarian cancer (PSROC), regardless of germline BRCA (gBRCA) mutation status, according to the final analysis of the NORA trial presented at SGO 2024.

Exposure to paclitaxel-coated devices (PCDs) does not appear to increase the risk of death among patients who are undergoing endovascular revascularization for lower limb peripheral artery disease, suggest the results of DETECT, a nationwide, retrospective cohort study. In contrast, exposure to PADs may even help lower the risk of mortality.

Patients with inadequately controlled hypertension (HTN) may benefit from a single subcutaneous (SC) injection of the investigational RNAi therapeutic zilebesiran, on top of standard antihypertensives, findings from the phase II KARDIA-2 trial suggest.

The US Food and Drug Administration (FDA) has approved the TriClip device for transcatheter edge-to-edge repair (TEER) in patients with severe tricuspid regurgitation (TR) or a leaky heart valve who are not eligible for surgery.

Treatment with plozasiran, an experimental small interfering–RNA drug that targets apolipoprotein C3 (APOC3) gene, helps regulate triglyceride levels, bringing them below the critical threshold associated with acute pancreatitis for most patients with severe hypertriglyceridemia, according to the phase IIb SHASTA-2* study.

The US Food and Drug Administration (FDA) has approved aprocitentan for the treatment of uncontrolled hypertension (HTN) in adults.

Gartisertib, an oral inhibitor of ataxia telangiectasia and Rad3-related protein (ATR), for patients with advanced solid tumours is well tolerated at lower doses, according to the results of a phase I study. However, unexpected liver toxicity prevents dose escalation and, in turn, limits the drug’s antitumour activity.